ICD-10-CM 2027 diagnosis code
D3A.8Other benign neuroendocrine tumors
D3A.8 is a valid, billable ICD-10-CM code for other benign neuroendocrine tumors. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.
Code unchanged since ICD-10-CM took effect on October 1, 2015. Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data
About D3A.8
D3A.8 is the ICD-10-CM diagnosis code for other benign neuroendocrine tumors. It belongs to category D3A (benign neuroendocrine tumors), block D3A (benign neuroendocrine tumors) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.
Within D3A, choose D3A.8 (Other benign neuroendocrine tumors) only when documentation doesn't support a more specific option: benign carcinoid tumors (D3A.0).
Use an additional code to identify any associated endocrine syndrome, such as: carcinoid syndrome (E34.00).
It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.
In MS-DRG v44.0, it is part of the grouping logic for DRG 826 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC, relative weight 4.7581), DRG 827 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC, relative weight 2.3896), DRG 828 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCC, relative weight 1.6955), DRG 829 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures with CC/MCC, relative weight 3.1281), DRG 830 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC, relative weight 1.4859), DRG 843 (Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCC, relative weight 1.9453) and 2 more, in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.
Before ICD-10, this condition was coded in ICD-9-CM as 209.60 (benign carcinoid tumor of unknown primary site).
Coding notes
- Neuroendocrine tumor NOS
Notes that apply from higher levels
Instructions written at a parent level also apply to D3A.8.
Broader instructions also apply from Chapter 2: Neoplasms.
MS-DRG v44.0 grouping
All DRGs →Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.
MDC 17 · Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
- 826Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCCRW 4.7581
- 827Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CCRW 2.3896
- 828Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCCRW 1.6955
MDC 17 · Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
MDC 17 · Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
- 843Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCCRW 1.9453
- 844Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with CCRW 1.2551
- 845Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses without CC/MCCRW 0.8447
ICD-9-CM equivalent
Converter →- 209.60Benign carcinoid tumor of unknown primary siteapproximate
From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
- No changes since FY2016.
Common questions about D3A.8
Is D3A.8 billable?
- Yes. D3A.8 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
Can D3A.8 be used as a principal diagnosis?
- Yes. The Medicare Code Editor doesn't restrict D3A.8 as a principal diagnosis.
Is D3A.8 a CC or MCC?
- No. D3A.8 is neither a CC nor an MCC under MS-DRG v44.0.
What DRG does D3A.8 group to?
- D3A.8 is used in the MS-DRG v44.0 logic for MS-DRG 826 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC), MS-DRG 827 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC), MS-DRG 828 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCC), MS-DRG 829 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures with CC/MCC), MS-DRG 830 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC), MS-DRG 843 (Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCC) and 2 more. Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.
What is the ICD-9 code for D3A.8?
- The CMS General Equivalence Mappings map D3A.8 to ICD-9-CM 209.60.